A previous report indicates that the inhibition of FcγRIIa-mediated platelet activation signaling, either through receptor blockade, IgG depletion or Syk inhibition, robustly reduced in vitro platelet hyperactivation induced by the plasma of COVID-19 patients [22]. This evidence concerns the gene SYK and COVID-19.